Is LSA (Morning Glory) legal in Belgium?

Legal status

LSA (ergine) is not reached by the Belgian controlled drug lists on the text checked here. The search found no entry: Annex II names lysergide and Annex IV limb B names selected lysergamides including 1P-LSD, LSZ and methylisopropyllysergamide, but neither names ergine or lysergic acid amide, and Annex IVA carries no generic ergoline or lysergamide family. The dossier puts this one squarely: LSA is not LSD. Belgium names particular lysergamides and has no generic ergoline structure, so similarity to lysergide is not enough to bring this compound in. That makes this a positive absence rather than a silence: the dossier records that before any absence was entered, the search moved through Annexes I to IV, all eight Annex IVA generic families, Annex V, product specific royal decrees, the EU precursor schedules, the AFMPS human and veterinary medicine database and the applicable food, plant, tobacco, alcohol or chemical product route. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them.

Consequences if caught

Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. On this row no controlled drug ladder attaches either. Article 2bis of the Law of 24 February 1921 reaches substances the King has listed, and LSA (ergine) is not on that list, so it supplies no band, no aggravated ceiling and no fine on this row. Separate product, food, tobacco, alcohol, medicines or veterinary penalties sit outside this row unless it states one, and it states none. The reason is the classification itself rather than a lenient penalty: the absence was recorded only after the named lysergamide entries and the eight generic families were both checked. Where a material described by this name in fact contains a listed substance, article 2(14) reaches it as a preparation and the article 2bis ladder then applies to that content.

If prescribed or medical

The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. LSA (ergine) is not in Annexes I to IV at all on this row's finding, so there is nothing here for the exception to except, and a travel question about it is a medicines or product question rather than a controlled drug one. There is no placement, because the named lysergamide entries do not include this one. No route specific to LSA (ergine) was found in this dossier and none has been invented for it.

Documentation

Carry the distinction with you rather than the family resemblance. Several lysergamides are named entries in Belgium and this one is not, so the answer turns on which compound is actually present. This was read on 18 September 2026 against the annex consolidation and the decree. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Drug laws and enforcement change and vary within a country. This is not legal advice. Always confirm with Belgium’s embassy or official drug authority before traveling; penalties can be severe, including imprisonment.